Role of immunosuppressive therapy in rheumatic diseases concurrent with COVID-19
Open Access
- 1 June 2020
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 79 (6), 737-739
- https://doi.org/10.1136/annrheumdis-2020-217460
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatologyNature Reviews Rheumatology, 2020
- Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseasesNature Reviews Rheumatology, 2020
- Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injuryThe Lancet, 2020
- Baricitinib as potential treatment for 2019-nCoV acute respiratory diseaseThe Lancet, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkersNature Reviews Rheumatology, 2016
- Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation SyndromeCritical Care Medicine, 2016
- Cyclosporine and tacrolimus for the treatment of rheumatoid arthritisCurrent Opinion in Rheumatology, 2007